March 1st Week, 2025 Regulatory Events 🎯  Bristol Myers Squibb ’ nivolumab (anti-PD-1) + ipilimumab (anti-CTLA-4) has been approved by...

February 4th Week, 2025 📝  Merck  & Co/  MSD 's sBLA for neoadjuvant pembro followed by adjuvant pembro + RT ± cisplatin in resectable,...

Highlights from the CHMP Feb 2025 Meeting are out! Here are the positive recommendations in the Oncology space: ⭐ New Therapies: 👉...

Welcome to the May edition of our CGT Watch newsletter!   CARsgen’s satri-cel priority review & Ph2 results; Autolus’ obe-cel positive...